Stable ascorbic acid compositions and methods of using same
Inventors
Copeland, Dan • DURHAM, Carolyn
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11890315-B2
Publication Date
2024-02-06
Expiration Date
Abstract
The application is directed a composition comprising organic acid (e.g., ascorbic acid), glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof, or any combination thereof, and methods of using the same. In certain aspects the application is directed to glutathione, a glutathione derivative, a glutathione conjugate, a pharmaceutically-acceptable salt thereof; and an organic acid; wherein the molar ratio is about 0.5-1:1. The composition can further comprises a bicarbonate salt, wherein the molar ratio is about 0.1-0.5:0.5-1:1.
Core Innovation
The invention relates to treating a subject having a pulmonary or airway viral infection by administering a therapeutically effective composition comprising glutathione, an ascorbic acid, and a bicarbonate. The composition defines a molar ratio of (a):(b):(c) about 0.1-0.5:0.5-1:1, where (a) is glutathione or a glutathione derivative, a glutathione conjugate, or a pharmaceutically-acceptable salt.
The invention further relates to upregulating mucociliary clearance in a subject suffering from a pulmonary or airway viral infection by administering a composition comprising glutathione or a glutathione derivative, a glutathione conjugate, or a pharmaceutically-acceptable salt, ascorbic acid, and bicarbonate. The composition again specifies the molar ratio of (a):(b):(c) about 0.1-0.5:0.5-1:1.
The disclosed support emphasizes pulmonary or airway viral infection and the associated airway inflammation and impaired airway clearance. The examples support improved mucociliary transport rate, reduced neutrophil extracellular traps and nitric oxide release, and decreased pro-inflammatory cytokines and inflammatory mediators.
Claims Coverage
The provided material includes two independent claims. Each independent claim centers on administering a three-component composition with a defined molar ratio of glutathione components, ascorbic acid, and bicarbonate.
Treating pulmonary or airway viral infection with glutathione, ascorbic acid, and bicarbonate
A method of treating a subject having a pulmonary or airway viral infection comprising administering a therapeutically effective amount of a composition comprising glutathione or a glutathione derivative, a glutathione conjugate, or a pharmaceutically-acceptable salt thereof, an ascorbic acid, and a bicarbonate, wherein the molar ratio of (a):(b):(c) is about 0.1-0.5:0.5-1:1.
Upregulating mucociliary clearance with glutathione, ascorbic acid, and bicarbonate
A method of upregulating mucociliary clearance in a subject suffering from a pulmonary or airway viral infection comprising administering a composition comprising glutathione or a glutathione derivative, a glutathione conjugate, or a pharmaceutically-acceptable salt thereof, an ascorbic acid, and a bicarbonate, wherein the molar ratio of (a):(b):(c) is about 0.1-0.5:0.5-1:1.
Across the independent claims, the inventive core is the administration of a glutathione, ascorbic acid, and bicarbonate composition with the specified molar ratio about 0.1-0.5:0.5-1:1, used either to treat pulmonary or airway viral infection or to upregulate mucociliary clearance.
Stated Advantages
Reduces airway inflammation in connection with pulmonary or airway viral infection.
Improves mucociliary transport rate and mucociliary clearance, including increased ciliary beat frequency and transport.
Exhibits antibacterial and anti-biofilm activity against clinical isolates.
Decreases neutrophil extracellular traps and nitric oxide release.
Decreases pro-inflammatory cytokines, including IL-6, IL-8, and TNF-α.
Decreases inflammatory mediators, including MMP-9 and MIP1α/MIP1β.
Reduces inflammatory output and results in clinical changes in exhaled NO and pulmonary function after nebulized dosing post lung transplant.
Documented Applications
Treatment of a subject having a pulmonary or airway viral infection using a glutathione, ascorbic acid, and bicarbonate-based composition with a specified molar ratio.
Upregulating mucociliary clearance in a subject suffering from a pulmonary or airway viral infection, including increasing ciliary beat frequency of airway epithelial cells.
Antibacterial and anti-biofilm use against clinical isolates as described in connection with the compositions.
Nebulized or inhaled delivery and suitability for administration by inhalation.
Combined use with CFTR therapies, including ivacaftor and lumacaftor.
Interested in licensing this patent?